Lenacapavir and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lenacapavir
Apixaban
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Lenacapavir (Sunlenca or Yeztugo) is an HIV medicine, and apixaban (Eliquis) is a blood thinner. Lenacapavir can slow down how your body breaks down and clears apixaban, so more apixaban can build up in your blood. That means the blood thinner may work a little too strongly, which can raise your chance of bleeding or bruising.
Watch for signs like unusual bruising, nosebleeds, bleeding gums, blood in your urine or stool, or bleeding that won't stop. The good news is that your care team knows about this and can manage it, often by keeping a closer eye on you. Please don't stop or change either medicine on your own, just check in with your pharmacist or doctor.
Effect: Increased apixaban exposure and elevated bleeding risk.
Mechanism: Apixaban is a substrate of CYP3A4 and P-gp (not a prodrug). Lenacapavir acts as a dual P-gp and moderate CYP3A4 inhibitor, reducing metabolism and efflux, so apixaban AUC and Cmax rise.
- Magnitude: By analogy to diltiazem (dual P-gp/moderate CYP3A4 inhibitor), apixaban Cmax rose ~31% and AUC ~39%.
- Onset: Unspecified; note lenacapavir's long half-life.
- Evidence: Probable.
- Management: Use with caution; monitor for bleeding. Dose may need individualization by the care team.
What happens
Increased apixaban exposure and increased risk of bleeding
Interaction Deep Dive
Apixaban is metabolized by both P-gp and CYP3A42, so giving it alongside an agent that inhibits both P-gp and moderately inhibits CYP3A4 can raise apixaban serum levels 5 and heighten the likelihood of bleeding 4. One pharmacokinetic study found that coadministration with diltiazem, an inhibitor of both P-gp and moderate CYP3A4, raised apixaban Cmax by 31% and AUC by 39% 5. Caution is advised when the two must be taken together 31.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated apixaban metabolism; inhibition of P-gp-mediated efflux transport of apixaban
How to manage this interaction
If both medicines are needed, the usual approach is caution and closer monitoring rather than stopping either drug.
- Keep taking both as prescribed unless your prescriber tells you otherwise.
- Your care team may watch you more closely for bleeding and may adjust and individualize your apixaban dose if appropriate.
- Report any unusual bruising, nosebleeds, bleeding gums, pink or red urine, black or bloody stools, or bleeding that won't stop.
- Tell any new provider or dentist that you take both drugs before procedures.
Raise any questions with your pharmacist or doctor, who can tailor the plan to you.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) In a retrospective observational analysis (N=426), the use of an agent that inhibits both P-gp and moderately inhibits CYP3A4 markedly raised bleeding risk among patients receiving apixaban or rivaroxaban for atrial fibrillation. Bleeding, defined as the composite of major, clinically relevant non-major, and minor bleeding, was seen in 26.4% of those taking an interacting agent compared with 18.4% in the propensity-matched control group (HR, 1.8; 95% CI, 1.19 to 2.73). The interacting agents were diltiazem (68.1%), amiodarone (26.8%), verapamil (5.7%), dronedarone (2.3%), and multiple agents (2.8%); none of the patients received concomitant erythromycin. When individual drug interactions were assessed, no significant differences in bleeding rates emerged, and the effects of renal dysfunction, the specific inhibitor, or the specific anticoagulant were not assessed 4.
b) Giving diltiazem, an inhibitor of both P-gp and CYP3A4 (moderate), together with apixaban raised apixaban Cmax by 31% and AUC by 39% relative to apixaban given by itself. A 10 mg oral dose of apixaban was given 8 days after starting diltiazem 360 mg once daily in 18 subjects 5.
Common questions
Can I take Lenacapavir and Apixaban together?
Lenacapavir can raise apixaban levels and increase bleeding risk, so your care team may monitor you more closely and adjust your dose. Keep taking both as prescribed and report any unusual bleeding or bruising. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Lenacapavir and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Lenacapavir and Apixaban interaction managed?
If both medicines are needed, the usual approach is caution and closer monitoring rather than stopping either drug. Keep taking both as prescribed unless your prescriber tells you otherwise. Your care team may watch you more closely for bleeding and may adjust and individualize your apixaban dose if appropriate. Report any unusual bruising, nosebleeds, bleeding gums, pink or red urine, black or bl… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Lenacapavir or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (5)
- Burnett AE, Mahan CE, Vazquez SR, et al: Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016; 41(1):206-232. PubMed
- Product Information: ELIQUIS(R) oral tablets, apixaban oral tablets. Bristol-Myers Squibb Company (per FDA), Princeton, NJ, 2019. DailyMed
- Steffel J, Collins R, Antz M, et al: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23(10):1612-1676.
- Hanigan S, Das J, Pogue K, et al: The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis 2020; 49(4):636-643. PubMed
- Frost CE, Byon W, Song Y, et al: Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 2015; 79(5):838-846.
Keep reading about Lenacapavir
Keep reading about Apixaban
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist